CXCR3 and neoplasm: In the MC38 tumor model, twice weekly intraperitoneal administration of a CXCR3-neutralizing antibody led to larger and heavier tumors at the study endpoint (Fig 6A and 6B), a strongly reduced infiltration of CD4+ and of CD8+ T-cells into the tumor mass (Fig 6C) and reduced IFN-γ and TNF-α production by the residual populations of both CD4+ and CD8+ T-cells (Fig 6D–6F).